Holen Sie sich die Stockscreener-App
0.4581
1.24%
0.0056
Handel nachbörslich:
.45
-0.0081
-1.77%
Schlusskurs vom Vortag:
$0.4525
Offen:
$0.4521
24-Stunden-Volumen:
493.62K
Relative Volume:
0.04
Marktkapitalisierung:
$8.91M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-11.79M
KGV:
-0.1368
EPS:
-3.3492
Netto-Cashflow:
$-9.72M
1W Leistung:
-5.91%
1M Leistung:
+18.99%
6M Leistung:
-27.44%
1J Leistung:
-78.19%
1-Tages-Spanne:
$0.4441
$0.4644
1-Wochen-Bereich:
$0.4345
$0.505
52-Wochen-Spanne:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.4581 | 9.47M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - Kalkine
ORCL: Oracle Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
An FDA hearing on psychedelic drugs is set for Sept. 14. Ensysce will take part. - Stock Titan
Ensysce completes PF614-MPAR-102 clinical enrollment - grafa.com
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Australia
Ensysce completes enrollment in opioid overdose study - Investing.com India
An opioid study from Ensysce is fully enrolled to test overdose protection - stocktitan.net
Ensysce Faces Nasdaq Delisting Risk After Cy Biopharma Deal Triggers Change of Control - minichart.com.sg
Ensys receives Nasdaq compliance notices but cleared equity rule; granted bid-price extension - TradingView
Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period - TradingView
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; After Earnings: The Stock Ends Down 3.87% for the Current SessionEarnings Yield Spread - vinanet.vn
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences director Bob G. Gower acquires common shares worth $443,025.17 - Bitget
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
Orrick Advises Cy Biopharma on Acquisition by Ensysce Biosciences and up to $77 Million Private Financing - orrick.com
Ensysce Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com South Africa
Ensysce Biosciences (ENSC) Drifts Lower as Shares Test Support Near $0.49Last Point Resistance - vinanet.vn
Ensysce completes Cy Biopharma acquisition, raises $21.5 million By Investing.com - Investing.com Australia
Ensysce Biosciences Acquires Cy Biopharma in Deal Backed by Up to $77 Million Financing - citybiz
Thursday's session: most active stocks - ChartMill
Ensysce Biosciences completes acquisition of Cy Biopharma - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition - AllSci
Ensysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing Package - Quiver Quantitative
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Ensysce completes Cy Biopharma acquisition, raises $21.5 million - Investing.com
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Ensysce Biosciences (ENSC) Dips 3.18% to $0.37, Nearing Critical Support ZoneNAAIM Exposure - vinanet.vn
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - Barchart.com
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ensysce Biosciences Inc-Aktie (ENSC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOWER BOB G | Director |
Aug 07 '26 |
Buy |
0.49 |
400,000 |
198,000 |
916,740 |
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):